GlassScriptPhysician profile
Norberto Alvarez
NPI 1730383324
$4,842.54
in general payments reported to CMS, 2019-2025
42 companies · $879 in 2025
The $879 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $885 · 2021: $788 · 2022: $440 · 2023: $675 · 2024: $802 · 2025: $879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,305 · Education: $51.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,305.12 |
| Education | $51.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $464.62 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $428.55 | 2020-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $389.60 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Merck Sharp & Dohme LLC | $360.48 | 2019-2025 | Verquvo, Steglatro, Belsomra |
| Glaxosmithkline, LLC. | $345.69 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $296.28 | 2021-2025 | |
| Corcept Therapeutics | $283.32 | 2021-2025 | Korlym |
| Amarin Pharma, INC. | $255.14 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.56 | 2019-2025 | Jardiance |
| Allergan, INC. | $152.32 | 2020 | |
| Esperion Therapeutics, INC. | $150.59 | 2020-2023 | Nexletol |
| Axsome Therapeutics, INC. | $112.64 | 2024-2025 | Auvelity |
| Amgen INC. | $110.38 | 2020-2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $110.19 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $103.49 | 2023-2025 | Quviviq, Quviviq |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norberto Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.